Efficacy of abiraterone and enzalutamide in patients who had disease progression within twelve months of completing docetaxel for metastatic castration sensitive prostate cancer.
Gang Chen(Zhuhai People's Hospital), Ravi A. Madan(National Cancer Institute), Lisa M. Cordes(National Institutes of Health Clinical Center), Amy Hankin(National Institutes of Health), Marijo Bilušić(National Institutes of Health), Guinevere Chun(Center for Cancer Research), Fatima Karzai(National Institutes of Health), James L. Gulley(National Cancer Institute), Philip M. Arlen(Dana-Farber Cancer Institute), David James VanderWeele(Northwestern University), William D. Figg(National Cancer Institute), Anna Couvillon(National Institutes of Health), Monique Williams(National Institutes of Health), Inger L. Rosner, William L. Dahut(National Cancer Institute), Helen Owens(National Institutes of Health), Munjid Al Harthy(Sultan Qaboos University)
Cited by 3
Related Papers
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2010|975
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817
Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
|Journal of Clinical Oncology|2014|714
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
|Cancer Immunology Research|2015|456
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
|Clinical Cancer Research|2018|415